Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study”

Ítems similars

• Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
  per: Akizawa, Tadao, et al.
  Publicat: (2018)
• Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients
  per: Shigematsu, Takashi, et al.
  Publicat: (2018)
• Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study
  per: Akizawa, Tadao, et al.
  Publicat: (2018)
• Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients
  per: Tsuruya, Kazuhiko, et al.
  Publicat: (2019)
• Correction to: Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients
  per: Tsuruya, Kazuhiko, et al.
  Publicat: (2019)